Nature Communications (Jul 2020)
Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer
- Léo Aubert,
- Neethi Nandagopal,
- Zachary Steinhart,
- Geneviève Lavoie,
- Sami Nourreddine,
- Jacob Berman,
- Marc K. Saba-El-Leil,
- David Papadopoli,
- Sichun Lin,
- Traver Hart,
- Graham Macleod,
- Ivan Topisirovic,
- Louis Gaboury,
- Christoph J. Fahrni,
- Daniel Schramek,
- Sylvain Meloche,
- Stephane Angers,
- Philippe P. Roux
Affiliations
- Léo Aubert
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- Neethi Nandagopal
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- Zachary Steinhart
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto
- Geneviève Lavoie
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- Sami Nourreddine
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- Jacob Berman
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
- Marc K. Saba-El-Leil
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- David Papadopoli
- Department of Oncology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University
- Sichun Lin
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto
- Traver Hart
- MD Anderson Cancer Center, University of Texas
- Graham Macleod
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto
- Ivan Topisirovic
- Department of Oncology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University
- Louis Gaboury
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- Christoph J. Fahrni
- School of Chemistry and Biochemistry, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology
- Daniel Schramek
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
- Sylvain Meloche
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- Stephane Angers
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto
- Philippe P. Roux
- Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, 2950, Chemin de la Polytechnique
- DOI
- https://doi.org/10.1038/s41467-020-17549-y
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
The oncogene KRAS is frequently mutated in cancer, including colorectal cancer. Here, using a cell-surface proteomics approach, KRAS-mutated colorectal cancer cells are shown to express high levels of the copper transporter ATP7A, which has an essential roles in cancer cell survival and proliferation.
